Clinical Trials Logo

Speech Disorders clinical trials

View clinical trials related to Speech Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04937452 Active, not recruiting - Dementia Clinical Trials

Dopaminergic Therapy for Frontotemporal Dementia Patients

Start date: June 3, 2021
Phase: Phase 2
Study type: Interventional

This is a phase IIa 24-week randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy and safety of Rotigotine (RTG) transdermal administration at the dosage of 4 mg or 6 mg per day versus Placebo (PLC) in newly diagnosed behavioural Frontotemporal Dementia (bvFTD) patients. 75 patients with a diagnosis of probable bvFTD will be randomly allocated to the 3 treatment arms (RTG 4mg/day, RTG 6mg/day or PLC), with 25 patients per group. Clinical and neurophysiological measurements and brain metabolism via FDG-PET will be collected before and after drug administration.